Head-to-head evidence
Dalcetrapib vs Dalcetrapib (RO4607381)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Atherosclerotic Cardiovascular Disease
Shared mechanism: CETP · full Atherosclerotic Cardiovascular Disease pipeline
Dalcetrapib
Developed by DalCor Pharmaceuticals under a licence from Japan Tobacco
NCT01516541 · Phase 3 · completed
The study was randomized and double-blind, compared dalcetrapib with placebo, and enrolled 2,220 participants. Its primary endpoint was a hard clinical composite cardiovascular outcome, but the comparison cannot be judged because trial results have not been posted.
Next expected readout: August 2027 · NCT05918861 (registry estimate)
Dalcetrapib (RO4607381)
Developed by Roche
NCT00655473 · Phase 2 · completed
The study randomized 130 participants to dalcetrapib or placebo and masked both participants and investigators. Its primary outcomes were surrogate MRI plaque measures rather than clinical events, and the registry does not state whether either comparison was statistically significant; the reported results were not clearly consistent across the two primary measures.
Next expected readout: August 2027 · NCT05918861 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Dalcetrapib's landscape · Dalcetrapib (RO4607381)'s landscape